REGENXBIO NASDAQ: RGNX outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives. The company said it expects to report top-line results later in the fourth quarter from its two pivotal wet AMD studies, ATMOSPHERE and ASCENT, in a planned joint release with partner AbbVie. REGENXBIO said the data could support a regu ...